# Natera, Inc.: insider transactions

NTRA · Nasdaq · CIK 1604821 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntra.md) · [Financials](/companies/ntra/financials.md) · [Filings](/companies/ntra/filings.md) · [Insiders](/companies/ntra/insiders.md)

## All transactions: 19

Non-derivative transactions reported on Forms 4, newest first. Codes P (purchase) and S (sale) are open-market trades. Reported price is as stated on the form, not a market price. Filter with ?type= `open-market`, `purchase`, `sale`.

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-28 | [Brophy Michael Burkes](/insiders/1697362.md) | CHIEF FINANCIAL OFFICER, Officer | Sale (S) | 1,198 | $426.3404 | $510.8k | [Form 4](/filings/0001697362-26-000020.md) |
| 2026-10-28 | [Fesko John](/insiders/2010135.md) | PRESIDENT, CHIEF BUS. OFFICER, Officer | Sale (S) | 898 | $426.3404 | $382.9k | [Form 4](/filings/0002010135-26-000025.md) |
| 2026-10-28 | [Rabinowitz Daniel](/insiders/1857843.md) | SEC. AND CHIEF LEGAL OFFICER, Officer | Sale (S) | 968 | $426.3404 | $412.7k | [Form 4](/filings/0001857843-26-000030.md) |
| 2026-10-28 | [Chapman Steven Leonard](/insiders/1711968.md) | CEO AND PRESIDENT, Director, Officer | Sale (S) | 3,430 | $426.3404 | $1.5m | [Form 4](/filings/0001711968-26-000027.md) |
| 2026-10-28 | [Moshkevich Solomon](/insiders/2010019.md) | PRESIDENT, CLINICALDIAGNOSTICS, Officer | Sale (S) | 1,162 | $426.3404 | $495.4k | [Form 4](/filings/0002010019-26-000035.md) |
| 2026-10-27 | [Brophy Michael Burkes](/insiders/1697362.md) | CHIEF FINANCIAL OFFICER, Officer | Sale (S) | 781 | $406.00 | $317.1k | [Form 4](/filings/0001697362-26-000020.md) |
| 2026-10-27 | [Fesko John](/insiders/2010135.md) | PRESIDENT, CHIEF BUS. OFFICER, Officer | Sale (S) | 781 | $406.00 | $317.1k | [Form 4](/filings/0002010135-26-000025.md) |
| 2026-10-27 | [Rabinowitz Daniel](/insiders/1857843.md) | SEC. AND CHIEF LEGAL OFFICER, Officer | Sale (S) | 884 | $406.00 | $358.9k | [Form 4](/filings/0001857843-26-000030.md) |
| 2026-10-27 | [Chapman Steven Leonard](/insiders/1711968.md) | CEO AND PRESIDENT, Director, Officer | Sale (S) | 2,264 | $406.00 | $919.2k | [Form 4](/filings/0001711968-26-000027.md) |
| 2026-10-27 | [Rabinowitz Matthew](/insiders/1646382.md) | EXECUTIVE CHAIRMAN, Director, Officer | Sale (S) | 1,718 | $406.00 | $697.5k | [Form 4](/filings/0001646382-26-000026.md) |
| 2026-10-27 | [Moshkevich Solomon](/insiders/2010019.md) | PRESIDENT, CLINICALDIAGNOSTICS, Officer | Sale (S) | 1,010 | $406.00 | $410.1k | [Form 4](/filings/0002010019-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 165 | $416.6736 | $68.8k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 255 | $415.6659 | $106.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 125 | $413.0476 | $51.6k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 211 | $412.1991 | $87.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 605 | $411.3175 | $248.8k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 627 | $409.8932 | $257.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 962 | $408.2584 | $392.7k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 200 | $406.50 | $81.3k | [Form 4](/filings/0001646649-26-000035.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 30, 2026, 21:35 ET. No prices; not investment advice.